🔎 Trials Near Me

Home › Interstitial Cystitis › NCT05149573

Investigation of PEMF Therapy for Female Patients With IC/BPS

Recruiting

Investigation of Non-Invasive Pulsed Electromagnetic Field (PEMF) Therapy for Female Patients With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Who can join

Ages 18 to 80 · Women

Full eligibility criteria
Inclusion Criteria:

* Previously established clinical diagnosis of IC/PS
* Current numeric rating scale (NRS) score of ≥ 6
* History of cystoscopy with hydrodistension with bladder capacity determination under anesthesia
* No cognitive deficits

Exclusion Criteria:

* History of bladder, ovarian, vaginal cancer
* History of urethral diverticulum
* History of radiation cystitis
* History of spinal cord injury or spina bifida
* History of Parkinson's disease, multiple sclerosis, or stroke
* Current placement of a pacemaker or metal prosthesis
* Active urinary tract infection
* BMI \> 40
* Residual urine of \> 100cc
* Current pregnant

About the study

The purpose of this study is to gather information about the safety and effectiveness of the non-pharmacological (non-drug), non-invasive treatment known as low-frequency pulsed electromagnetic field (PEMF) therapy. The study team will distribute the PEMF device to female adults with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) to measure its ability to decrease bladder and pelvic pain as well as other urinary symptoms associated with IC/BPS. There are two sequential Aims in this study and subjects will be recruited to participate in only one Aim. In both Aims, data will be collected at baseline/enrollment, 4-weeks after using PEMF therapy, and 8, 12, and 16 weeks post-enrollment.

What is being tested

Sponsor: Wake Forest University Health Sciences · Participants: 75 · Started: Aug 29, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05149573

Locations in the U.S.

North CarolinaWake Forest University Health Sciences, Winston-Salem

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.